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En  memoria  del  Dr.  Paul  Angulo  (20  de  abril  de  1965  -  25  de  febreron
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The  Gastroenterology  and  Hepatology  communities  are
deeply  saddened  by  the  unexpected  passing  of  Dr.  Paul
Angulo.  Paul  was  an  exceptional  clinical  researcher  who
earned  international  prestige  for  his  work  on  autoimmune
and  fatty  liver  disease.
He  obtained  his  Medical  degree  at  the  Universidad
Michoacana  de  San  Nicolás  de  Hídalgo  in  Mexico,  followed  by
a  research  fellowship  under  the  mentorship  of  Dr.  Guadalupe
Garcia-Tsao  at  the  Instituto  Nacional  de  Ciencias  Médicas  y
Nutrición  Salvador  Zubirán  in  Mexico  City.  He  subsequently
did  his  fellowship  in  Internal  Medicine,  where  he  was  Chief
Resident  during  the  last  year  and  also  ﬁnished  his  Gastroen-
terology  fellowship  in  the  same  Institute. Please cite this article as: Montano-Loza AJ. En memoria del Dr.
Paul Angulo (20 de abril de 1965 - 25 de febrero de 2015). Revista
de Gastroenterología de México. 2015;80:175--176.
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an open access article under the CC BY-NC-ND license (http://creativecoHe  then  relocated  to  the  Mayo  Clinic  in  Rochester,  Min-
esota,  to  start  a  postdoctoral  research  fellowship  under  the
utelage  of  Dr.  Keith  Lindor,  where  he  became  ﬁrst  an  Assis-
ant  and  eventually  an  Associate  Professor.  At  the  time  of
is  death,  Paul  was  a  full  Professor  of  Medicine  and  Section
hief  of  Hepatology  at  the  University  of  Kentucky.
Paul  was  highly  proliﬁc.  He  wrote  over  100  published
apers,  most  of  them  in  top-ranked  journals  such  as
he  New  England  Journal  of  Medicine,1 Gastroenterology,2
epatology3 and  the  Journal  of  Hepatology,4 among  many
thers.  One  of  his  major  achievements  was  the  devel-
pment  of  ﬁbrosis  scores  that  currently  constitute  the
ore  accepted  non-invasive  tool  for  predicting  ﬁbrosis
www.naﬂdscore.com)5 and  outcomes  in  patients  with  non-
lcoholic  fatty  liver  disease.6 Paul  was  also  invited  to
ive  numerous  international  presentations  that  included  the
igestive  Disease  Week  sponsored  by  the  American  Associa-
ion  of  Gastroenterology,  the  Liver  Meeting  of  the  American
ssociation  for  the  Study  of  Liver  Diseases,  and  the  Inter-
ational  Liver  Congress  of  the  European  Association  for
he  Study  of  the  Liver.  Moreover,  he  always  maintained  a
lose  relationship  with  the  Asociación  Mexicana  de  Gas-
roenterología,  participating  as  a  keynote  speaker  at  several
eetings  and  serving  as  part  of  the  editorial  board  of  the
evista  de  Gastroenterología  de  México,  the  ofﬁcial  jour-
al  of  our  association.  Those  of  us  who  had  the  opportunity
o  work  with  Paul7,8 had  the  privilege  of  beneﬁtting  from  his
owerful  personality.  As  a  mentor,  his  sincerity  was  constant
nd  he  deeply  valued  all  of  his  undergraduate  and  postgrad-
ate  students.  He  was  always  there  to  help  them  out  with
ny  issue,  major  or  minor.  He  was  unceasingly  enthusias-
ic  regarding  research,  and  his  excitement  was  contagious
nd  energizing.  Our  sorrow  from  the  irreparable  loss  of  a
reat  clinical  researcher  is  assuaged  through  the  remem-
rance  of  his  achievements  obtained  at  his  young  age  that
ill  prevail  in  beneﬁt  of  liver  disease  management  for  future
enerations.
.A. on behalf of Asociación Mexicana de Gastroenterología. This is
mmons.org/licenses/by-nc-nd/4.0/).
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‘‘Every  man  dies.  Not  every  man  really  lives’’  (William
oss  Wallace).
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